Tirzepatide vs reta (retatrutide) compared: how these two weekly injectables differ in mechanism, weight loss results, dosing, safety, and FDA status.
Tirzepatide and reta are not the same medication, and they are not at the same stage of development. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, while "reta" is shorthand for retatrutide, an investigational triple agonist that targets GLP-1, GIP, and glucagon receptors and is not approved for human use. The biggest practical difference is availability: one is a prescription drug you can fill today, and the other is only legally accessible through clinical trials.
Tirzepatide vs Reta at a Glance
The table below summarizes the main differences between these two weekly injectables. Keep in mind that retatrutide's numbers come from a mid-stage trial, while tirzepatide's come from large Phase 3 studies.
| Feature | Tirzepatide | Retatrutide (reta) |
|---|---|---|
| Receptor targets | GIP and GLP-1 | GLP-1, GIP, and glucagon |
| FDA status | Approved (Mounjaro, Zepbound) | Investigational, not approved |
| How it is taken | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Weight loss in trials | About 21% at 72 weeks (15 mg) | About 24% at 48 weeks (12 mg) |
| Common side effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, vomiting, constipation, heart rate increase |
| Availability in the US | Prescription only | Clinical trials only |
How Their Mechanisms Differ
Tirzepatide is a dual agonist, which means it activates two gut-hormone receptors: GIP and GLP-1. Those receptors drive appetite suppression, slower stomach emptying, and improved blood sugar control.
Retatrutide adds a third receptor: glucagon. Glucagon receptor activation raises energy expenditure and increases fat oxidation, which is one reason researchers expect stronger weight loss from a triple agonist.
That extra mechanism also explains why retatrutide is monitored for effects tirzepatide does not typically cause, including a measurable rise in resting heart rate.
Weight Loss Results Compared
In its Phase 2 trial, retatrutide produced average weight reductions of roughly 24% at 48 weeks in participants taking the 12 mg dose. In the SURMOUNT-1 trial, tirzepatide 15 mg produced average weight reductions of about 21% at 72 weeks.
Those numbers are not directly comparable. They come from different trial sizes, populations, dose schedules, and durations, and no head-to-head trial has directly compared tirzepatide and retatrutide.
If you have searched retatrutide vs tirzepatide: which is better, the most accurate answer today is that retatrutide looks at least as potent in early data but has not been proven superior in a controlled comparison.
For broader context, people reviewing semaglutide vs tirzepatide weight loss results generally see larger average reductions with tirzepatide. Retatrutide appears to push that ceiling a little higher, but the gap is smaller than headlines suggest.
Dosing and How You Take Them
Both drugs are injected subcutaneously once a week, usually into the abdomen, thigh, or upper arm. Tirzepatide is titrated slowly to limit gastrointestinal side effects.
| Drug | Starting dose | Highest studied dose | Titration |
|---|---|---|---|
| Tirzepatide | 2.5 mg weekly | 15 mg weekly | Increase every 4 weeks |
| Retatrutide | 1 mg weekly in trial protocols | 12 mg weekly | Stepwise, per trial protocol |
Tirzepatide dosing is standardized in its FDA label. Retatrutide dosing is still experimental, and the amount used in a trial may not match what unregulated suppliers advertise.
Side Effects and Safety
The two drugs share a similar gastrointestinal profile because both act on GLP-1 signaling.
- Nausea, vomiting, and diarrhea are the most common complaints.
- Constipation, indigestion, and reduced appetite are also frequent.
- Serious risks include pancreatitis, gallbladder disease, and dehydration from persistent vomiting.
- Retatrutide has also been linked to increased heart rate and reports of dysesthesia, a tingling or burning skin sensation.
Tirzepatide has a much larger safety database because millions of prescriptions have been filled since approval. Retatrutide's long-term safety profile is still being characterized in Phase 3 trials.
Both drugs are prescription-strength therapies that require medical supervision, and neither should be purchased from unverified online sellers.
FDA Approval and Availability in the US
Tirzepatide is approved by the FDA: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It is available by prescription through retail and mail-order pharmacies.
Retatrutide is not FDA-approved for any indication. It is being studied in the Phase 3 TRIUMPH program, and it can only be obtained legally by enrolling in a clinical trial.
Products marketed as "reta" or "retatrutide" outside of trials are typically research chemicals of unknown purity. Buying them carries a real risk of dosing errors and contamination.
How Reta Compares With Other Options
Retatrutide is not the only drug being stacked against tirzepatide in research. Combination therapy research such as cagrisema vs tirzepatide is testing whether adding an amylin analog improves results beyond what GLP-1 and GIP activation alone can achieve.
Most tesamorelin vs tirzepatide discussions focus on visceral fat specifically, because tesamorelin was studied for that narrow purpose rather than for general weight loss.
These comparisons matter because the field is moving toward multi-receptor drugs, and retatrutide is the clearest example of that trend.
Bottom Line: Is Reta Better Than Tirzepatide?
Retatrutide is not proven to be better than tirzepatide, but early data suggests it may produce somewhat greater weight loss. Tirzepatide is the safer practical choice today because it is approved, widely available, and supported by far more safety data.
Anyone considering either medication should talk with a licensed healthcare professional about risks, contraindications, and appropriate monitoring.
Frequently Asked Questions
Is reta better than tirzepatide for weight loss?
In Phase 2 data, retatrutide produced about 24% average weight loss at 48 weeks, slightly more than tirzepatide's roughly 21% at 72 weeks in SURMOUNT-1. However, no head-to-head trial has compared the two drugs, so "better" is not proven. Tirzepatide is FDA-approved while retatrutide is still investigational.
Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA for any use in the United States and remains an investigational drug. It is being studied in the Phase 3 TRIUMPH program, so it can legally be obtained only by enrolling in a clinical trial.
Can you take tirzepatide and retatrutide together?
Combining tirzepatide and retatrutide has not been studied, and there is no evidence it adds benefit. Stacking two GLP-1-based drugs would likely increase side effects such as nausea, vomiting, and dehydration without proven extra weight loss. Only a licensed clinician should change or combine weight-loss medications.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.